Call for papers - Reproduction, Technology and Society, a new section in Reproductive BioMedicine Online
Page URL: https://www.bionews.org.uk/page_92296

Gene patents may be damaging the genetic testing market, study claims

19 April 2010
Appeared in BioNews 554

Researchers examining gene patents used in diagnostic tests say these can block competition and slow innovation, rather than spur development of new technologies for assessing the risk of genetic diseases. A team at Duke University, Durham, US, looked at case studies of genetic risk testing for ten clinical conditions, including cystic fibrosis and breast cancer. These were chosen as examples of different uses of patents, the effect of which could be isolated.

Universities held most of the patents. These were then licensed out to pharmaceutical companies, some who held exclusive rights to the gene sequence involved in disease and any tests for it. Seven of the conditions were linked to exclusive licenses, but in no case was the rights holder the first to market with a test. 'That finding suggests that while exclusive licenses have proved valuable for developing drugs and biologics that might not otherwise have been developed, in the world of gene testing they are mainly a tool for clearing the field of competition', said Dr Robert Cook-Deegan, Director of the IGSP Centre for Genome Ethics, Law and Policy at Duke University, and lead author of the study. He said the problem does not lie with patents themselves, but how they are being licensed. 'Whilst I don't want to make sweeping statements, exclusive licensing needs to be done with extreme caution', he said.

Another issue highlighted by the report was development of multi-gene - or even whole-genome - scans was being slowed by the need to get permission from many rights holders. The scientists suggest that patents and the lure of exclusivity are not required to spur the development of diagnostic tests. They say their cystic fibrosis case study shows that, although the gene sequence was non-exclusively licensed, dozens of laboratories developed tests for it and competed on the basis of service, innovation and quality.

However, Mr John Murphy, General Counsel at SkyePharma, and Chairman of the Intellectual Property Committee at the BioIndustry Association, says it's difficult to argue from one case, and that the use of patents here may not work for, and enhance, the overall industry. 'The need for patents and the monopolies they ensure has been tested over many years, we need this system to encourage innovation and investment', he said.

The report comes at a time when there are several pending legal battles around gene patents. A US judge recently overturned two patents belonging to Myriad Genetics and used in its breast cancer risk test. Dr Anton Hutter, a European Patent Attorney at Venner Shipley, said he hoped the verdict would be overruled: 'without gene patents I can't see how manufacturers will continue to develop and market these tests'. 

The Duke University study is published in Genetics in Medicine.

SOURCES & REFERENCES
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
19 December 2011 - by Nishat Hyder 
A patent for a diagnostic test is currently under consideration by the US Supreme Court. The eventual decision may have profound implications for the burgeoning 'personalised medicine' industry which often relies on DNA tests to guide physicians in choosing tailored therapies for patients...
14 November 2011 - by Martin Turner 
In what appears to be the end of a long running legal saga, a ruling by the UK's Supreme Court has found in favour of a patent for a gene and the protein sequence it encodes. Lawyers say that the ruling will make it easier to patent discoveries which do not have a clear demonstrated application, a result that will largely please the private bioscience industry but may alarm many who believe that human genes should not be patentable....
22 August 2011 - by Antony Starza-Allen 
The United States Patent and Trademark Office (USPTO) has granted its first patent associated with induced pluripotent stem (iPS) cell technology to Professor Shinya Yamanaka of Kyoto University, Japan, for a technique used to reprogram fully differentiated somatic mouse cells into an embryonic-like state...
17 January 2011 - by Rose Palmer 
This is an extraordinary book about a woman who died on 4 October 1951, but whose legacy will continue exponentially. Henrietta Lacks was a poor black tobacco farmer who died, aged only 31, in the 'coloured ward' of John Hopkins Hospital in Baltimore....
8 November 2010 - by Dr Nadeem Shaikh 
The US Department of Justice (DOJ) has weighed in on the complex issue of gene patenting against the principle that genes should be eligible for patent protection, reversing the government's position on the matter and causing consternation for many biotechnology companies. This week it issued a legal brief as a 'friend of the court' joining a lawsuit challenging the rights of companies to patent genetic technologies....
6 April 2010 - by Dr Vivienne Raper 
A US judge has invalidated a genetic testing company's patents on two breast cancer genes...
8 November 2009 - by Dr Marianne Kennedy 
A lawsuit challenging the patents relating to two genes linked to hereditary breast and ovarian cancer will proceed, a US federal judge ruled last week....
10 August 2009 - by Antony Starza-Allen 
A Senate Committee in Australia is hearing arguments for and against gene patenting with a view to propose future law reforms in this area. Opponents of gene patents argue that it can restrict access to vital diagnostic techniques, such as breast cancer screening, which identify certain genes that indicate the presence of a disorder. On the other hand...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.